Transforming lives through innovative antibody therapeutics.

one30 Therapeutics is a cutting-edge biotechnology company dedicated to transforming lives through innovative antibody therapeutics. Our unique platform allows us to target one, two or multiple disease genes to address unmet healthcare needs with the goal of enhancing the wellbeing of the global population.

–Our Science–

A new paradigm for treating inflammatory diseases: selective targeting of gp130 signalling pathways

Established monotherapies target the IL6 family of cytokines but disease complexity is not addressed

Cytokine Signalling via gp130:
Multiple Drug Targets

Existing gp130 family cytokine therapy approaches focus largely only on one target, but it has been shown that multiple cytokines contribute to complex disease phenotypes.

one30’s founders have developed a novel approach to target gp130 to selectively and simultaneously neutralise multiple (two or more) cytokine members.

The cytokine-selective gp130 antibody platform of one30 Therapeutics

Specific mAb-based inhibition of IL6 and IL11

VVB611

Blocks IL-6 and IL-11 selectively
Anti-inflammatory, anti-fibrotic and pro-regeneration combination therapy in a single molecule
Unique utility for kidney injury and attenuate cardiovascular risk

Pan mAb-based inhibition of gp130 cytokines

VVB130

Powerful anti-inflammatory that blocks IL-6, IL-11, OSM, LIF, CNTF and CT-1
Targets a range of severe inflammatory diseases

VVB130:VEGFi

Combines global gp130 blockade with VEGF inhibition
Multikine inhibitor to treat connective tissue perturbation
Developed for use in eye disease

Specific mAb-based inhibition of IL6 and IL11

VVB611

Blocks IL-6 and IL-11 selectively
Anti-inflammatory, anti-fibrotic and pro-regeneration combination therapy in a single molecule
Unique utility for kidney injury and attenuate cardiovascular risk

Pan mAb-based inhibition of gp130 cytokines

VVB130

Powerful anti-inflammatory that blocks IL-6, IL-11, OSM, LIF, CNTF and CT-1
Targets a range of severe inflammatory diseases

VVB130:VEGFi

Combines global gp130 blockade with VEGF inhibition
Multikine inhibitor to treat connective tissue perturbation
Developed for use in eye disease

–Pipeline–

Our Pipeline

Swipe left and right to view full pipeline.

CKD: Chronic kidney disease, RA: Rheumatoid arthritis, CVD: Cardiovascular disease, AKI: Acute kidney injury, HS: Hidradenitis suppurativa, SSc: Systemic sclerosis (scleroderma), IPF: Idiopathic pulmonary fibrosis, CSS: cytokine storm syndrome, AMD: Age-related macular degeneration

–Team–

Founded by biotech leaders with proven track record

one30 Therapeutics was founded in 2020 by an experienced multidisciplinary team of scientists and entrepreneurs who have previously developed first-in-class IL-11 antibodies to treat fibrotic diseases.